CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced that it is canceling its participation in the Goldman Sachs 45th Annual Global Healthcare Conference due to weather-related flight disruptions. Prior to this announcement, the Company was scheduled to participate on June 13, 2024, at 8:00 am ET. Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of i ...

CHARLOTTE, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. William Blair 44th Annual Growth Stock Conference on June 5, 2024, at 9:20 am CT (10:20 am ET) Goldman Sachs 45th Annual Global Healthcare Conference on June 13, 2024, at 8:00 am ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the ...

On May 01, 2024, the court issued an order granting in part and denying in part defendants' motion to dismiss and gave leave to amend the complaint. Those who purchased DENTSPLY SIRONA Inc. (NASDAQ: XRAY) shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim fi ...

NEW ORLEANS, May 24, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Dentsply Sirona, Inc. (NasdaqGS: XRAY). On April 19, 2022, the Company disclosed the sudden termination of CEO Donald Casey "effective immediately." Then, on May 10, 2022, the Company disclosed an ongoing investigation by its Audit and Finance Committee, outside counsel and a forensic accou ...

CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 12, 2024, to holders of record as of June 28, 2024. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of inno ...

CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 12, 2024, to holders of record as of June 28, 2024. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of inno ...

Have you evaluated the performance of Dentsply International's (XRAY) international operations for the quarter ending March 2024? Given the extensive global presence of this dental products manufacturer, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. In ...

Financial Data and Key Metrics - Q1 2024 revenue was $953 million, a decline of 2.6% YoY, with organic sales down 1.9% [9] - Adjusted EPS was $0.42, an increase of nearly 8% YoY, in line with expectations despite softer sales [6] - EBITDA margins expanded by 30 basis points due to restructuring savings and net investment hedges [53] - Operating cash flow improved to $25 million compared to an outflow of $21 million in the prior year quarter [53] - Cash and cash equivalents stood at $291 million as of March 31, 2024, with a leverage ratio of 2.6x [53] Business Line Performance - **Connected Technology Solutions (CTS):** Organic sales declined 5.7%, driven by double-digit declines in imaging equipment, partially offset by high single-digit growth in CAD/CAM [55] - **Essential Dental Solutions (EDS):** Organic sales declined 5.5% due to a tough YoY comp, as Q1 2023 saw 11.5% growth [54] - **Orthodontic and Implant Solutions:** Organic sales grew 5.6%, with aligners up 14% and Byte growing 18% [54] - **Wellspect HealthCare:** Organic sales grew 5%, with mid-single-digit growth expected for the full year [55] Regional Performance - **US:** Organic sales grew 1.4%, driven by strong growth in aligners and CAD/CAM, partially offset by lower imaging equipment sales [56] - **Europe:** Organic sales declined 5.8%, with Germany down double digits due to prolonged recessionary trends [56] - **Rest of World:** Organic sales were flat, with significant growth in China offset by softer demand in Japan and Canada [56] Strategic Direction and Industry Competition - The company is focusing on innovation, with DS Core adoption rates increasing and new products like Axano Pure and Midwest Energo being launched [7] - The reintroduction of Orthophos SL in Europe aims to address competitive pressures in imaging equipment [7] - The company is investing in high-growth categories like orthodontics, implants, and continence care, with Byte Plus expanding commercially [28] - Sustainability remains a key focus, with Wellspect HealthCare achieving emission reduction targets validated by the Science Based Targets initiative [8] Management Commentary on Operating Environment and Future Outlook - Management noted macroeconomic challenges, particularly in Germany, impacting imaging equipment sales [4][6] - The company is maintaining its full-year outlook for organic sales and adjusted EPS but trending towards the low end of the ranges due to macro uncertainties [6] - Management expressed confidence in the long-term trajectory, citing a comprehensive portfolio and progress on strategic objectives [6] Other Important Information - The company plans to execute up to $150 million in share repurchases in Q2 2024 [6] - SKU rationalization efforts are underway, focusing on endo and resto portfolios, with benefits expected to accrue in 2025 and 2026 [76] Q&A Session Summary Question: Update on growth expectations for each business segment [31] - **Answer:** EDS expected to be flat for the full year, Ortho to grow over 20%, implants to grow low single digits, CTS to decline mid-single digits, and Wellspect to grow mid to high single digits [32][33][34] Question: North America implants business update [35] - **Answer:** Growth expected in H2 2024, with market growth in implants estimated at mid-single digits [36] Question: Pricing strategy and competitive positioning [38] - **Answer:** The reintroduction of Orthophos SL addresses a gap in the imaging portfolio, offering value and premium options [39] Question: Gross margin sustainability [46] - **Answer:** Gross margins expected to remain consistent with Q1 levels, around 56.6%, for the rest of the year [46] Question: Byte growth sustainability [63] - **Answer:** Byte growth is driven by investments in treatment planners, advertising, and financing options, with profitability expected to improve [64] Question: DS Core metrics and quantification [70] - **Answer:** DS Core has over 20,000 accounts, with aggressive subscription goals for 2024 [71] Question: SKU rationalization impact [76] - **Answer:** SKU rationalization is focused on endo and resto portfolios, with operational efficiencies being realized now and more benefits expected in 2025 and 2026 [76]

DENTSPLY SIRONA Inc. (XRAY) reported first-quarter 2024 adjusted earnings per share (EPS) of 42 cents, which aligns with the Zacks Consensus Estimate. The bottom line improved 7.9% on a year-over-year basis.On a GAAP basis, the company reported an EPS of 9 cents against the loss of 9 cents per share reported in the year-ago quarter.RevenuesRevenues in the reported quarter totaled $953 million, which missed the Zacks Consensus Estimate by 1.8%. The top line declined 2.6% year over year and 1.9% on an organic ...

For the quarter ended March 2024, Dentsply International (XRAY) reported revenue of $953 million, down 2.6% over the same period last year. EPS came in at $0.42, compared to $0.39 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $969.84 million, representing a surprise of -1.74%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.42.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...